EmeritusDX Acquires Sprint Diagnostics
July 2, 2024
EmeritusDX, a cancer diagnostics and information company, has entered a definitive agreement to acquire Sprint Diagnostics to expand its Pharma Services Division. The acquisition adds advanced diagnostic capabilities and laboratory production capacity to EmeritusDX's CLIA-certified operations, supporting growth in pharmaceutical and clinical trial services.
- Buyers
- EmeritusDX
- Targets
- Sprint Diagnostics
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
mdxhealth to Acquire Bio-Techne’s Exosome Diagnostics Business (ExoDx Prostate)
August 5, 2025
Healthcare Services
Bio-Techne Corporation has reached an agreement for mdxhealth SA to acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test and CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to proprietary exosome-based technology for ongoing kit development, and expects the transaction to be completed in the first quarter of fiscal 2026.
-
Quest Diagnostics Acquires Haystack Oncology
April 27, 2023
Healthcare Services
Quest Diagnostics has agreed to acquire Haystack Oncology in an all-cash transaction valued at $300 million at closing plus up to $150 million in potential milestones. The acquisition adds Haystack's sensitive ctDNA-based minimal residual disease (MRD) liquid biopsy technology to Quest's oncology, genomics and pathology capabilities to expand clinical lab services for MRD testing beginning in 2024.
-
EmeritusDX Acquires Freedom Pathology Partners
June 13, 2022
Healthcare Services
EmeritusDX, a cancer diagnostics and information company, has acquired Freedom Pathology Partners, a CAP- and CLIA-accredited laboratory based in Conshohocken, Pennsylvania. The acquisition expands EmeritusDX’s national presence and test menu—adding anatomic pathology, FISH, and molecular testing capabilities and strengthening relationships in dermatology, gastroenterology, and urology markets.
-
Quest Diagnostics Acquires Pack Health
January 18, 2022
Healthcare Services
Quest Diagnostics has entered into a definitive agreement to acquire Pack Health in an all-cash transaction. The acquisition brings Pack Health's patient-engagement platform and certified health coaches into Quest's Extended Care services to strengthen value-based care and connect diagnostic insights to action.
-
Invitae Acquires ArcherDX to Build a Precision Oncology Genetics Platform
June 22, 2020
Healthcare Services
Invitae has entered into a definitive agreement to acquire ArcherDX in a cash-and-stock transaction valued at approximately $1.4 billion, combining Invitae's diagnostic and hereditary testing capabilities with ArcherDX's somatic genomics, liquid biopsy and bioinformatics platform. The deal is intended to integrate germline and somatic testing, expand precision oncology offerings, and accelerate adoption of comprehensive cancer genetics across clinical and biopharma customers worldwide.
-
Exact Sciences Acquires Paradigm Diagnostics and Viomics
March 3, 2020
Healthcare Services
Exact Sciences Corp. has completed the acquisitions of Phoenix-based Paradigm Diagnostics, Inc. and Viomics, Inc., adding a late-stage therapy selection genomic profiling test, a scalable clinical lab, and sequencing/biomarker discovery capabilities to its precision oncology portfolio. The deals (financial terms largely undisclosed in the company release) bring Paradigm and Viomics into Exact Sciences’ research and commercial platform to accelerate tissue- and blood-based advanced cancer diagnostics.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.